Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer

Cancer Letters

Volumn 375, Issue 1, 2016, Pages 114-126

  Zou, Peng ^a,b   Xia, Yiqun ^c   Ji, Jiansong ^d   Chen, Weiqian ^a,d   Zhang, Jinsan ^a   Chen, Xi ^a   Rajamanickam, Vinothkumar ^a   Chen, Gaozhi ^a   Wang, Zhe ^a   Chen, Lingfeng ^a   Wang, Yifeng ^a   Yang, Shulin ^b   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^d LISHUI CENTRAL HOSPITAL   (China)

Author keywords

ER stress; Mitochondrial dysfunction; Piperlongumine; Reactive oxygen species; Thioredoxin reductase 1

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; BUTHIONINE SULFOXIMINE; CASPASE 3; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PIPERLONGUMINE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; BCL2 PROTEIN, HUMAN; PIPERLONGUMININE; TXNRD1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENDOPLASMIC RETICULUM STRESS; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG SCREENING; METABOLISM; NUDE MOUSE; PATHOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DIOXOLANES; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; STOMACH NEOPLASMS; THIOREDOXIN REDUCTASE 1; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960123339     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.058     Document Type: Article

References (42)

1. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
2. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
3. Rudalska R., Dauch D., Longerich T., McJunkin K., Wuestefeld T., Kang T.W., et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat. Med 2014, 20:1138-1146.
4. Korkaya H., Kim G.I., Davis A., Malik F., Henry N.L., Ithimakin S., et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 2012, 47:570-584.
5. Harris I.S., Treloar A.E., Inoue S., Sasaki M., Gorrini C., Lee K.C., et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 2015, 27:211-222.
6. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
7. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
8. Sena L.A., Chandel N.S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 2012, 48:158-167.
9. Wiseman H., Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J. 1996, 313(Pt 1):17-29.
10. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov 2009, 8:579-591.
11. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
12. Jeanne M., Lallemand-Breitenbach V., Ferhi O., Koken M., Le Bras M., Duffort S., et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010, 18:88-98.
13. Alexandre J., Hu Y., Lu W., Pelicano H., Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 2007, 67:3512-3517.
14. Gao N., Rahmani M., Dent P., Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 2005, 24:3797-3809.
15. Raj L., Ide T., Gurkar A.U., Foley M., Schenone M., Li X., et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011, 475:231-234.
16. Chen Y., Liu J.M., Xiong X.X., Qiu X.Y., Pan F., Liu D., et al. Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP. Oncotarget 2015, 6:6406-6421.
17. Powis G., Mustacich D., Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med 2000, 29:312-322.
18. Mustacich D., Powis G. Thioredoxin reductase. Biochem. J. 2000, 346(Pt 1):1-8.
19. Rigobello M.P., Bindoli A. Mitochondrial thioredoxin reductase purification, inhibitor studies, and role in cell signaling. Methods Enzymol 2010, 474:109-122.
20. Li C., Peng Y., Mao B., Qian K. Thioredoxin reductase: a novel, independent prognostic marker in patients with hepatocellular carcinoma. Oncotarget 2015, 6:17792-17804.
21. Esen H., Erdi F., Kaya B., Feyzioglu B., Keskin F., Demir L.S. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades. J. Neurooncol 2015, 121:451-458.
22. Zou P., Zhang J., Xia Y., Kanchana K., Guo G., Chen W., et al. ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer. Oncotarget 2015, 6:5860-5876.
23. Ouyang X., Zhou S., Su C.T., Ge Z., Li R., Kwoh C.K. CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints. J. Comput. Chem 2013, 34:326-336.
24. Konermann S., Brigham M.D., Trevino A.E., Joung J., Abudayyeh O.O., Barcena C., et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 2015, 517:583-588.
25. Eriksson S.E., Prast-Nielsen S., Flaberg E., Szekely L., Arner E.S. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic. Biol. Med 2009, 47:1661-1671.
26. Duan D., Zhang B., Yao J., Liu Y., Fang J. Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells. Free Radic. Biol. Med 2014, 70:182-193.
27. Cai W., Zhang L., Song Y., Wang B., Zhang B., Cui X., et al. Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic. Biol. Med 2012, 52:257-265.
28. Fiskus W., Saba N., Shen M., Ghias M., Liu J., Gupta S.D., et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res 2014, 74:2520-2532.
29. Du Y., Zhang H., Lu J., Holmgren A. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose. J. Biol. Chem 2012, 287:38210-38219.
30. Verfaillie T., Rubio N., Garg A.D., Bultynck G., Rizzuto R., Decuypere J.P., et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ 2012, 19:1880-1891.
31. Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011, 334:1081-1086.
32. Tabas I., Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol 2011, 13:184-190.
33. Zinszner H., Kuroda M., Wang X., Batchvarova N., Lightfoot R.T., Remotti H., et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998, 12:982-995.
34. Weinberg S.E., Chandel N.S. Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol 2015, 11:9-15.
35. Esen H., Feyzioglu B., Erdi F., Keskin F., Kaya B., Demir L.S. High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression. Brain Tumor Pathol 2015, 32(3):195-201.
36. Bragado P., Armesilla A., Silva A., Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 2007, 12:1733-1742.
37. Fan C., Chen J., Wang Y., Wong Y.S., Zhang Y., Zheng W., et al. Selenocystine potentiates cancer cell apoptosis induced by 5-fluorouracil by triggering reactive oxygen species-mediated DNA damage and inactivation of the ERK pathway. Free Radic. Biol. Med 2013, 65:305-316.
38. Urig S., Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol 2006, 16:452-465.
39. Bezerra D.P., Pessoa C., de Moraes M.O., Saker-Neto N., Silveira E.R., Costa-Lotufo L.V. Overview of the therapeutic potential of piplartine (piperlongumine). Eur. J. Pharm. Sci 2013, 48:453-463.
40. Kim T.H., Song J., Kim S.H., Parikh A.K., Mo X., Palanichamy K., et al. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro Oncol 2014, 16:1354-1364.
41. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
42. Xiang T., Du L., Pham P., Zhu B., Jiang S. Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway. Cancer Lett 2015, 364:79-88.